Brief: Sino Biopharmaceutical Updates On Phase III Registrational Clinical Study Of TQB2868 Injection
10/06/2025 11:28
June 10 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: CDE APPROVAL TO INITIATE PHASE III REGISTRATIONAL CLINICAL STUDY OF TQB2868 INJECTION PD-1/TGF- BI-FUNCTIONAL FUSION PROTEIN Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit